A Phase I Study to Investigate the Safety Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2018
At a glance
- Drugs Tinostamustine (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Planned End Date changed from 1 Oct 2021 to 1 Oct 2020.
- 13 Aug 2018 Status changed from not yet recruiting to recruiting.